- Home
- JANX vs EYPT Comparison
JANX vs EYPT Comparison
Compare JANX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | EYPT |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | JANX | EYPT |
|---|---|---|
| Price | $14.16 | $18.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $60.27 | $29.60 |
| AVG Volume (30 Days) | ★ 3.3M | 1.3M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,000,000.00 | ★ $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.76 | $3.91 |
| 52 Week High | $61.59 | $19.11 |
Technical Indicators
Market Signals| Indicator | JANX | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 28.18 | 66.55 |
| Support Level | $13.82 | $16.52 |
| Resistance Level | $14.49 | $19.00 |
| Average True Range (ATR) | 0.61 | 1.01 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 9.76 | 74.24 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.